Implicit Bioscience
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Implicit Bioscience sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Implicit Bioscience: 4 sponsored US clinical trials, 2 recruiting.
Implicit Bioscience sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), with 1 trials.
Upper-quartile sponsor footprint
Implicit Bioscience sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
NCT06513949
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
NCT06678074
IC14 for Treatment of Acute Decompensated Heart Failure
NCT06556810
IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy
NCT06275893
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Implicit Bioscience pipeline
2 recruiting of 4 indexed (50% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) (1 trial), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Implicit Bioscience: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Implicit Bioscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Implicit Bioscience page
4 registered trials is a research-attention snapshot, not an endorsement of Implicit Bioscience or any single study.
- 2 of Implicit Bioscience's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) is the condition Implicit Bioscience studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Implicit Bioscience pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.